Yunfei Chen

Dr. Yunfei Chen


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2017 in SLEEP
Verified
Journal Article
Closed access
PDF file
CFCong Fu
Cong Fu
NZNa Zhao
Na Zhao
ZLZhen Liu
Zhen Liu
LYLu-Hua Yuan
Lu-Hua Yuan
CXChen Xie
Chen Xie
YCYunfei Chen
Yunfei Chen
To evaluate the short-term efficacy of acupuncture for the treatment of peri-menopausal insomnia (PMI). Design: A randomized, participant-blind, placebo-controlled trial consisted of the acupuncture group (n = 38) and placebo-acupuncture group (n = 38). Setting: A tertiary teaching and general hospital. Participants: 76 peri-menopausal women with insomnia disorder based on the International Classification of Sleep Disorders, Third Edition. Interventions: A 10-session of acupuncture at bilateral Shenshu (BL 23) and Ganshu (BL 18) with unilateral Qimen (LR 14) and Jingmen (GB 25) or Streitberger needles at the same acupoints was performed for over 3 weeks. Measurements: Pittsburgh Sleep Quality Index (PSQI) and Insomnia Severity Index (ISI) with over-night polysomnography (PSG) exam were completed at baseline and post-treatment. After the treatments, the decrease from baseline in PSQI score was 8.03 points in acupuncture group and 1.29 points in placebo-acupuncture group. The change from baseline in ISI score was 11.35 points in acupuncture group and 2.87 points in placebo-acupuncture group. In PSG data, acupuncture significantly improved the sleep efficiency and total sleep time, associated with less wake after sleep onset and lower percent stage 1 after the treatment. No significant differences from baseline to post-treatment were found in placebo-acupuncture group. Acupuncture can contribute to a clinically relevant improvement in the short-term treatment of PMI, both subjectively and objectively. Acupuncture for peri-menopause insomnia: a randomized controlled trial, http://www.chictr.org.cn/showproj.aspx?proj=12118 ChiCTR-IPR-15007199, China.

14 September 2023 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
BKBrett King
Brett King
JSJerry Shapiro
Jerry Shapiro
MOManabu Ohyama
Manabu Ohyama
AEAlexander Egeberg
Alexander Egeberg
Bianca Maria PiracciniBianca Maria Piraccini
Bianca Maria Piraccini
YDYves Dutronc
Yves Dutronc
Baricitinib is approved for the treatment of adults with severe alopecia areata (AA). In the absence of robust data on the patterns of regrowth during treatment of severe AA, there is a gap in the knowledge regarding treatment expectations. To examine whether different clinical response subgroups could be identified in baricitinib-treated patients with severe AA and factors that contribute to these subgroups. The BRAVE-AA1 and BRAVE-AA2 phase III trials enrolled patients with severe AA [Severity of Alopecia Tool (SALT) score ≥ 50 (≥ 50% scalp hair loss)]. Patients randomized to baricitinib 4 mg or 2 mg retained their treatment allocation for 52 weeks. Based on patterns identified through growth mixture modelling (GMM), patients were categorized into responder subgroups according to when they first achieved ≥ 30% improvement from baseline in SALT score (SALT30). For each responder subgroup, trajectories of response (i.e. achievement of a SALT score ≤ 20, SALT score ≤ 10 and ≥ 50% change from baseline in SALT score) and baseline disease characteristics are reported. Respectively, 515 and 340 patients were randomized to once-daily baricitinib 4 mg and 2 mg at baseline; 69% and 51%, respectively, achieved SALT30 at least once by week 52. Based on GMM findings, we identified three responder subgroups: early (SALT30 by week 12), gradual (SALT30 after week 12–week 36) and late (SALT30 after week 36–week 52). The proportions of early, gradual and late responders and nonresponders were, respectively, 33%, 28%, 8% and 31% among patients treated with baricitinib 4 mg, and 20%, 23%, 9% and 49%, respectively, among those treated with baricitinib 2 mg. Early responders had a shorter trajectory to maximal clinical outcomes (e.g. > 78% achieved a SALT score ≤ 20 by week 36) vs. gradual or late responders. Early responders were more frequent among patients with baseline severe AA (SALT score 50 to < 95) vs. very severe AA (SALT score 95–100). Overall, responders (early to late) were more frequent in patients with short (< 4 years) episodes of hair loss. These analyses identified early, gradual and late responder subgroups for scalp hair regrowth in baricitinib-treated patients with severe AA, and that these subgroups are influenced by baseline characteristics. Findings from these analyses will help to inform treatment expectations for scalp hair regrowth.

1 October 2021 in Nature and Science of Sleep
Verified
Journal Article
Open access
PDF file
CWCong Wang
Cong Wang
WXWen-Lin Xu
Wen-Lin Xu
GLGuan-Wu Li
Guan-Wu Li
CFCong Fu
Cong Fu
JLJin-Jin Li
Jin-Jin Li
YCYunfei Chen
Yunfei Chen
Study Objectives: To evaluate the efficacy and safety of acupuncture at HT 7 (Shenmen) and KI 7 (Fuliu) on sleep and comorbid symptoms for chronic insomnia. Methods and Design: A randomized, single-blind, parallel and sham-controlled trial consisted of an acupuncture group (n = 41) and a sham acupuncture group (n = 41). Setting: a tertiary hospital of integrated Chinese and Western medicine. Participants: 82 subjects with chronic insomnia based on the International Classification of Sleep Disorders, Third Edition (ICSD-3). Interventions: a 10-session acupuncture treatment at bilateral HT 7 and KI 7 or sham acupoints with shallow needling was performed over 3 weeks. Measurements: the Pittsburgh sleep quality index (PSQI) and insomnia severity index (ISI) were evaluated at baseline, posttreatment, and at two follow-ups as the primary outcome measures. Polysomnography (PSG) on two consecutive nights, the Beck anxiety inventory (BAI), the Beck depression inventory (BDI) fatigue severity scale (FSS) and the Epworth sleepiness scale (ESS) were evaluated at baseline and posttreatment as the secondary outcome measures. Results: After the treatments, PSQI scores decreased by 5.04 in the acupuncture group and 2.92 in the sham acupuncture group. ISI scores decreased by 7.65 in the acupuncture group and 5.05 in the sham acupuncture group. The between-group differences in the primary outcome measures posttreatment were statistically significant. However, no differences were found between the two groups during the two follow-ups. Regarding the PSG data, there were significantly lower levels of sleep onset latency (SOL), a lower percentage of sleep stage N1 and a higher percentage of sleep stage N3 in the acupuncture group than in the sham acupuncture group. After treatment, there were lower levels of comorbid symptoms (BAI, BDI, FSS and ESS) in both groups. However, no significant differences were observed between the groups. Conclusion: Acupuncture at HT 7 and KI 7 is an effective and safe nonpharmacologic intervention option for chronic insomnia. Clinical Trial Registration: The study was registered at the Chinese Clinical Trial Registry, registration ID: ChiCTR1900023787, China.

1 July 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
CXChen Xie
Chen Xie
JWJing Wang
Jing Wang
NZNa Zhao
Na Zhao
WYWenjia Yang
Wenjia Yang
XGXiaolin Gao
Xiaolin Gao
XYXintong Yu
Xintong Yu
Background. Insomnia is often related to stressful events. The hypothalamus-pituitary-adrenal (HPA) axis is related to stress, and dopamine (DA) and DA receptors are involved in the regulation of HPA axis. Electroacupuncture (EA) can improve sleep in individuals with insomnia, but the mechanism is unclear. We demonstrated that EA can improve sleep in rats after cage change through DA and the DA receptors in the HPA axis. Methods. A rat model of insomnia was established by cage change to a dirty cage. The rats in treatment groups were intervened by EA and D1R (or D2R) antagonists. Electroencephalography (EEG) and electromyogram (EMG) were recorded to compare the changes in sleep. The DA, corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and cortisol (CORT) levels in the plasma and hypothalamus were measured by ELISAs, and the D1R and D2R levels were measured by RT-PCR and immunohistochemistry. Results. The dirty group showed a significant increase in the amount of wakefulness and decrease in the amount of NREM sleep, with decreased numbers of long NREM sleep bouts and REM sleep bouts and increased mean duration of wakefulness during the light period. EA and D1R (or D2R) antagonists intervention could improve sleep disturbance by decreasing wakefulness in the light period after cage change, EA and D1R (or D2R) antagonists could increase the hypothalamus DA, CRH, ACTH, CORT level, and the D1R and D2R mRNA levels in the HPA axis, and the effect of EA plus D1R (or D2R) antagonist was not superior to that of EA or D1R (or D2R) antagonists alone. Conclusions. EA can improve the sleep of rats after cage change, and the mechanism may be related to the regulation of DA and D1R or D2R in the HPA axis.

1 November 2020 in Energy Reports
Verified
Journal Article
Open access
WJWei Jiang
Wei Jiang
YCYunfei Chen
Yunfei Chen

29 December 2023 in Journal of Acupuncture and Tuina Science
Verified
Journal Article
Open access
PDF file
WYWenjia Yang
Wenjia Yang
XYXintong Yu
Xintong Yu
NZNa Zhao
Na Zhao
CXChen Xie
Chen Xie
JLJinjin Li
Jinjin Li
YCYunfei Chen
Yunfei Chen
Objective: To observe the effects of kidney-tonifying and mind-calming acupuncture therapy on sleep, mood, sex hormone levels, and traditional Chinese medicine (TCM) symptoms in patients with perimenopausal insomnia (PMI). Methods: A total of 90 patients with PMI were randomly divided into a treatment group and a control group, with 45 cases in each group. Patients in the treatment group were treated with acupuncture at Shenshu (BL23), Taixi (KI3), Baihui (GV20), and Anmian (Extra). The control group was treated with sham acupuncture. Both groups were treated 3 times a week for 4 weeks. Pittsburgh sleep quality index (PSQI) and insomnia severity index (ISI) were used to evaluate the sleep quality of the subjects before treatment, after treatment, and 1 month after treatment (follow-up). Beck depression inventory (BDI) and Beck anxiety inventory (BAI) were used to evaluate the depression and anxiety of the subjects before treatment, after treatment, and at 1-month follow-up. The TCM symptom scale was used to evaluate the TCM symptoms of the subjects before treatment, after treatment, and 1 month after treatment. Serum levels of estradiol (E2), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were measured before and after treatment. Results: During the study, 2 cases dropped out of the treatment group, and no cases dropped out of the control group. The PSQI scores of the treatment group were significantly lower after treatment and at 1-month follow-up compared with those before treatment (P<0.05), and the difference was statistically significant compared with that of the control group (P<0.05). In the control group, the PSQI score was significantly lower after treatment compared with before treatment (P0.05). Compared with the pre-treatment, the ISI, BDI, BAI, and TCM symptom scale scores of the treatment group were lower after treatment and at 1-month follow-up (P<0.05), and the differences with the control group at the same time point were statistically significant (P0.05). After treatment, the serum E2 level in the treatment group was significantly higher than that before treatment (P<0.05), and the difference with the control group was statistically significant (P0.05). The differences in the serum FSH and LH levels between before and after treatment were not statistically significant in either group of subjects (P>0.05). Conclusion: Kidney-tonifying and mind-calming acupuncture therapy can improve sleep quality, relieve anxiety and depression, delay the decrease of serum E2 level, and improve related TCM symptoms in patients with PMI.